Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma

Mark Baxter, Lindsay Spender, Russell Petty (Lead / Corresponding author)

Research output: Contribution to journalEditorialpeer-review

Abstract

A trial update confirms improved survival for prophylactic elective nodal irradiation and addition of erlotinib to definitive chemoradiotherapy in oesophageal squamous cell carcinoma (ESCC). High tumour EGFR protein expression shows promise to identify those who will benefit from erlotinib. This represents therapeutic progress, and has wider relevance for precision medicine strategies in ESCC.
Original languageEnglish
Pages (from-to)1585-1587
Number of pages3
JournalBritish Journal of Cancer
Volume123
Issue number11
Early online date22 Sep 2020
DOIs
Publication statusPublished - 24 Nov 2020

Keywords

  • Oesophageal cancer

Fingerprint Dive into the research topics of 'Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this